Syndax Pharmaceuticals (SNDX) EBIT Margin Growth (1y) (2016 - 2026)
Analysis
Syndax Pharmaceuticals (SNDX) EBIT Margin Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -1,651.00 |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 29,091.00 |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn | 12,776.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12,776.00 |
| Mar 31, 2026 | 36,518.00 |
| Dec 31, 2025 | 116,374.00 |
| Sep 30, 2025 | 59,143.00 |
| Jun 30, 2025 | 193,775.00 |
| Dec 31, 2021 | 530,196.00 |
| Sep 30, 2021 | 507,638.00 |
| Jun 30, 2021 | -151,029.00 |
| Mar 31, 2021 | -318,285.00 |
| Dec 31, 2020 | -148,816.00 |
| Sep 30, 2020 | -176,887.00 |
| Jun 30, 2020 | -32,612.00 |
| Mar 31, 2020 | -7,625.00 |
| Dec 31, 2019 | 134,947.00 |
| Sep 30, 2019 | 123,799.00 |
| Jun 30, 2019 | 94,380.00 |
| Mar 31, 2019 | 130,343.00 |
| Dec 31, 2018 | -345,402.00 |
| Sep 30, 2018 | 35,687.00 |
| Jun 30, 2018 | -46,190.00 |